The benefits of a new vaccine based on an allogeneic plasmacytoid DC cell line have been investigated.
In recent years, immunotherapy has finally found its place in the anti-cancer therapeutic arsenal, even becoming a standard of care as a first-line treatment for metastatic forms. However, many patients are resistant to these treatments due to poor underlying cancer immunity.
A New Cancer Vaccine
Therefore, there is a need to increase the frequency and function of patients’ cytotoxic CD8+ cell effectors by targeting immunogenic and tumor-restricted antigens as neoantigens using an effective vaccine platform.
Dendritic cells (DC) are the most potent immune cell subset to trigger a cellular immune response. However, autologous DC-based vaccines show several limitations, such as the lack of reproducibility and the limited number of cells that can be produced.
“NeoAgs appear to be attractive candidates for generating specific anti-tumor responses in cancer patients on classical tumor-associated antigens and in combination with ICIs. A potent dendritic cell product such as PDC*neo is a valuable platform for the development of NeoAg-based cancer vaccines. We believe that this new delivery technology based on this technology can generate a strong anti-NeoAg CD8+ T-cell immune response for the benefit of patients and reshape the landscape of NeoAg-based cancer vaccines.”